| Field | Specification |
|---|---|
| Mfr No | |
| Clonality | |
| Host | |
| Immunogen | A recombinant partial protein sequence (within amino acids 1-298) from the human protein was used as the immunogen for the CREB3L4 antibody. |
| Isotype | |
| Product Type | |
| Purity | |
| Reactivity | |
| Storage | |
| Target | |
| UniProt # |
Overview
CREB3L4 Antibody / AIBZIP is an antibody targeting CREB3L4. Host: Mouse. Monoclonal. Clone: PCRP-CREB3L4-1A3. Format: Purified. Applications: FACS, IF, IHC-P.
Key elements and design rationale
- Target: CREB3L4.
- Immunogen: A recombinant partial protein sequence (within amino acids 1-298) from the human protein was used as the immunogen for….
- Species reactivity: Human.
- Localization: Nucleus.
- Conjugate: Unconjugated (no label listed).
Biological background (from provided description)
CREB3L4 is a transcriptional activator that may play a role in the unfolded protein response.
Common research applications
- IHC: tissue distribution assessment; interpret with matched controls.
- IF/ICC: subcellular localization imaging with proper background controls.
Notes for experimental interpretation
- Account for isoforms, paralogs, and post-translational modifications when interpreting signal.
- Support specificity with biological controls (e.g., KO/KD where available) and technical controls (e.g., secondary-only/isotype).
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
